This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

EC to set 22 September deadline for Novartis, EBEWE; and Sony, Seiko Epson deals

By Dafydd Nelson ( August 19, 2009, 11:06 GMT | Insight) -- Healthcare and pharmaceuticals company Novartis has notified its planned acquisition of Austrian pharmaceuticals company EBEWE Pharma to the European Commission for merger control review. In addition, electronic device manufacturer Sony has also submitted its intended purchase of certain assets of Seiko Epson’s liquid crystal display business to the regulator. Both deals are expected to face a 22 September Phase I deadline (corrects*).Healthcare and pharmaceuticals company Novartis has notified its planned acquisition of Austrian pharmaceuticals company EBEWE Pharma to the European Commission for merger control review. In addition, electronic device manufacturer Sony has also submitted its intended purchase of certain assets of Seiko Epson’s liquid crystal display business to the regulator....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login